Paclitaxel Export Market Intelligence: India's 319 Suppliers Shipping to 142 Countries — TransData Nexus 2026

Q: Who are the top paclitaxel exporters from India?

The top paclitaxel exporters from India are: 1. FRESENIUS KABI ONCOLOGY LIMITED — $25.1M (30.2% market share); 2. MSN LABORATORIES PRIVATE LIMITED — $7.7M (9.3% market share); 3. INTAS PHARMACEUTICALS LIMITED — $5.9M (7.1% market share); 4. JODAS EXPOIM PRIVATE LIMITED — $5.9M (7.1% market share); 5. PANACEA BIOTEC PHARMA LIMITED — $5.7M (6.9% market share). Together they account for 60.7% of India's total paclitaxel export value.

Q: What is the total export value of paclitaxel from India?

The total export value of paclitaxel from India is $83.1M USD, recorded across 4,928 shipment transactions from 319 active exporters to 142 destination countries. The average shipment value is $16.9K.

Q: Which countries import paclitaxel from India?

India exports paclitaxel to 142 countries worldwide. The top importing countries are: GERMANY (20.6% share, $17.2M), UNITED STATES (13.1% share, $10.9M), RUSSIA (7.0% share, $5.9M), CANADA (7.0% share, $5.8M), THAILAND (5.6% share, $4.7M). These five markets account for 53.4% of total export value.

Q: What is the HS code for paclitaxel exports from India?

The primary HS code for paclitaxel exports from India is 30049044. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of paclitaxel exports from India?

The average unit price for paclitaxel exports from India is $16.32 USD per unit, with prices ranging from $0.01 to $2799.75 depending on formulation, packaging, and order volume. The total market is valued at $83.1M across 4,928 shipments.

Q: Which ports handle paclitaxel exports from India?

The primary ports for paclitaxel exports from India are DELHI AIR CARGO ACC (INDEL4) (16.8% of shipments), SAHAR AIR (12.5% of shipments), DELHI AIR (12.2% of shipments), SAHAR AIR CARGO ACC (INBOM4) (11.2% of shipments), HYDERABAD AIR (3.8% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of paclitaxel?

India is one of the world's leading exporters of paclitaxel due to its large base of 319 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports paclitaxel to 142 countries, demonstrating 73% global market coverage.

Q: What certifications do Indian paclitaxel exporters need?

Indian paclitaxel exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import paclitaxel from India?

There are 959 registered buyers importing paclitaxel from India, spread across 142 countries. The repeat buyer rate is 60.9%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top paclitaxel supplier from India?

FRESENIUS KABI ONCOLOGY LIMITED is the leading paclitaxel exporter from India with a market share of 30.2% and total export value of $25.1M across 854 shipments. The top 5 suppliers together control 60.7% of total export value.

Suresh Sormare

Paclitaxel

India Pharmaceutical Trade Intelligence

$83.1M319 Suppliers142 CountriesHS 30049044

ExportsIndia → GERMANY20.6%India → UNITED STATES13.1%

ImportsSOUTH KOREA → India$1.6B UNITED STATES → India$2.3M

#1 Supplier: FRESENIUS KABI #1 Buyer: FRESENIUS KABI

Paclitaxel Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Paclitaxel to the World

Between 2022 and 2026, India exported $83.1M worth of paclitaxel across 4,928 verified shipments to 142 countries — covering 73% of world markets in the Oncology segment. The largest destination is GERMANY (20.6%). FRESENIUS KABI ONCOLOGY LIMITED leads with a 30.2% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049044

Paclitaxel export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Paclitaxel export data snapshot — $83.1M · 319 exporters · 142 countriesTransData Nexus · Indian Customs Data

Top Paclitaxel Exporters from India

319 active exporters · Ranked by export value

View all 319 →

Top Paclitaxel Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	FRESENIUS KABI ONCOLOGY LIMITED	$25.1M	854	24	30.2%
2	MSN LABORATORIES PRIVATE LIMITED

Top Countries Importing Paclitaxel from India

142 destination markets · Ranked by import value

All 142 countries →

Top Countries Importing Paclitaxel from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	GERMANY	$17.2M	20.6%
2	UNITED STATES	$10.9M	13.1%
3	RUSSIA	$5.9M	7.0%
4	CANADA	$5.8M	7.0%
5	THAILAND	$4.7M	5.6%
6	MOROCCO	$4.6M	5.5%
7	BRAZIL	$2.5M	3.0%
8	PHILIPPINES	$2.5M	3.0%
9	COLOMBIA	$2.4M	2.8%
10	MALTA	$2.1M	2.5%

GERMANY is India's largest paclitaxel export destination, absorbing 20.6% of total exports worth $17.2M. The top 5 importing countries — GERMANY, UNITED STATES, RUSSIA, CANADA, THAILAND — together account for 53.4% of India's total paclitaxel export value. The remaining 137 destination countries collectively receive the other 46.6%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Paclitaxel to India?

19 origin countries · Total import value: $1.6B

India imports paclitaxel from 19 countries with a combined import value of $1.6B. The largest supplier is SOUTH KOREA ($1.6B, 27 shipments), followed by UNITED STATES and CANADA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Paclitaxel to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	SOUTH KOREA	$1.6B	27	99.7%
2	UNITED STATES	$2.3M	48	0.1%
3	CANADA	$1.5M	6	0.1%
4	CHINA	$252.9K	6	0.0%
5	TAIWAN	$162.4K	2	0.0%
6	NETHERLANDS	$99.9K	7	0.0%
7	GERMANY	$74.0K	6	0.0%
8	UNITED KINGDOM	$69.4K	4	0.0%
9	HUNGARY	$67.3K	2	0.0%
10	SINGAPORE	$35.2K	1	0.0%

Showing top 10 of 19 origin countries

SOUTH KOREA is the largest supplier of paclitaxel to India, accounting for 99.7% of total import value. The top 5 origin countries — SOUTH KOREA, UNITED STATES, CANADA, CHINA, TAIWAN — together supply 100.0% of India's paclitaxel imports. Click any country to see detailed supplier and buyer data for that import corridor.

Paclitaxel — Export Intelligence Video

Visual overview of India's paclitaxel import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's paclitaxel pharmaceutical import and export market — $83.1M in total trade, 319 verified manufacturers, and 142 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Paclitaxel

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, paclitaxel is approved under multiple Abbreviated New Drug Applications (ANDAs), indicating a well-established generic market. The FDA's Orange Book lists numerous approved ANDAs for paclitaxel, reflecting its widespread acceptance and use. Recent approvals include those for generic versions by various manufacturers, underscoring the competitive landscape. As of March 2026, there are no active import alerts related to paclitaxel, suggesting compliance with FDA standards among Indian exporters. The regulatory pathway for paclitaxel involves demonstrating bioequivalence to the reference listed drug, ensuring safety and efficacy. With 319 active Indian exporters and a repeat buyer rate of 60.9%, the US market remains a critical destination for Indian paclitaxel exports.

2EU & UK Regulatory Framework

In the European Union, paclitaxel is subject to stringent marketing authorization processes overseen by the European Medicines Agency (EMA). Notably, on February 9, 2024, the European Commission withdrew the marketing authorization for Apealea, a paclitaxel formulation, at the request of the marketing authorization holder due to commercial reasons. This withdrawal highlights the dynamic nature of the EU pharmaceutical market. Manufacturers must adhere to EU Good Manufacturing Practice (GMP) requirements, ensuring product quality and safety. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) maintains similar standards, necessitating compliance for market entry.

3WHO Essential Medicines & Global Standards

Paclitaxel is included in the World Health Organization's Model List of Essential Medicines, underscoring its critical role in cancer treatment. This inclusion facilitates its adoption in national essential medicines lists, such as that of Seychelles in 2024. Compliance with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for global market acceptance.

4India Regulatory Classification

In India, paclitaxel is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for compliance with export regulations.

5Patent & Exclusivity Status

The primary patents for paclitaxel have expired, leading to a robust generic market. However, certain formulations, such as Abraxane, have patents extending into the 2030s, affecting market dynamics. The presence of multiple generic manufacturers indicates significant competition in the market.

6Recent Industry Developments

In June 2024, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for Imfinzi in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer. This development may influence paclitaxel demand in the EU market.

In January 2026, the CHMP adopted a positive opinion recommending a new indication for Zynyz in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. This expansion of indications could impact paclitaxel utilization.

These developments reflect the evolving regulatory landscape and the importance of paclitaxel in combination therapies for various cancers.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Paclitaxel

Retail & reference prices across 4 markets vs. India FOB export price of $16.32/unit

Global Price Benchmark for Paclitaxel across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$51.04	USD	According to a WHO report published in November 2025, the average price per treatment cycle in the U.S. is $51.04.
United Kingdom	$171.14	GBP	The same WHO report indicates an average price of $171.14 per treatment cycle in the UK.
Brazil	$350.68	BRL	As per the WHO report from November 2025, Brazil's average price per treatment cycle is $350.68.
IndiaORIGIN

Supply Chain Risk Assessment — Paclitaxel

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Paclitaxel, a critical chemotherapeutic agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This dependency exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing facilities, disrupting the supply of essential KSMs. For instance, in July 2018, the closure of Chinese companies impacted Indian pharmaceutical players, leading to increased prices of APIs due to the rise in KSM costs. Such disruptions underscore the risks associated with over-reliance on a single country for critical raw materials.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 60.7% of Paclitaxel exports, with FRESENIUS KABI ONCOLOGY LIMITED alone contributing 30.2% ($25.1M USD). This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the global supply chain.

Access Complete Paclitaxel Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 4,928 transactions across 142 markets.

Request Demo View Pricing

Frequently Asked Questions — Paclitaxel Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top paclitaxel exporters from India?

The leading paclitaxel exporters from India are FRESENIUS KABI ONCOLOGY LIMITED, MSN LABORATORIES PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED, and 12 others. FRESENIUS KABI ONCOLOGY LIMITED leads with 30.2% market share ($25.1M). The top 5 suppliers together control 60.7% of total export value.

What is the total export value of paclitaxel from India?

The total export value of paclitaxel from India is $83.1M, recorded across 4,928 shipments from 319 active exporters to 142 countries. The average shipment value is $16.9K.

Which countries import paclitaxel from India?

India exports paclitaxel to 142 countries. The top importing countries are GERMANY (20.6%), UNITED STATES (13.1%), RUSSIA (7.0%), CANADA (7.0%), THAILAND (5.6%), which together account for 53.4% of total export value.

What is the HS code for paclitaxel exports from India?

The primary HS code for paclitaxel exports from India is 30049044. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Paclitaxel

Paclitaxel

Top Paclitaxel Exporters from India

Top Countries Importing Paclitaxel from India

Who Supplies Paclitaxel to India?

Quick Facts

Related Oncology

Related Analysis

Need Details?

Paclitaxel — Export Intelligence Video

Regulatory Landscape — Paclitaxel

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Paclitaxel

Supply Chain Risk Assessment — Paclitaxel

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Paclitaxel Trade Intelligence

Frequently Asked Questions — Paclitaxel Exports from India

Who are the top paclitaxel exporters from India?

What is the total export value of paclitaxel from India?

Which countries import paclitaxel from India?

What is the HS code for paclitaxel exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of paclitaxel exports from India?

Which ports handle paclitaxel exports from India?

Why is India a leading exporter of paclitaxel?

What certifications do Indian paclitaxel exporters need?

How many buyers import paclitaxel from India?

What is the market share of the top paclitaxel exporter from India?

Analysis Methodology